HEALTHCARE

The company has developed a miniature heart pump that can be inserted into the body through minimally invasive surgery.

Six of the world’s top 10 pharma companies use CytoReason’s technology to make data-driven decisions in immunology, inflammation, immuno-oncology, metabolism, and other therapeutic areas.

The sale to Edwards Lifesciences vindicates Innovalve's solution for the most common, and most challenging, heart valve disorder, and also Sheba Hospital's innovation model.

Swedish company Mölnlycke Health Care, an international leader in the field of treating wounds, led the private placement.

Sources estimate that Edwards will pay more than $300 million for Innovalve's trans-catheter mitral valve replacement device.

The Israeli businessman's long term aim is to build Phcann in the medical cannabis market in Europe including the UK, as well as in Australia.

The Israeli company has developed a pineapple-plant based product for treatment of burns and wounds.

Alcon will make an immediate payment of $81 million and a further $385 million in milestone payments, according to the product's success on the market.

K Health CEO Allon Bloch: K Health solves the need to make primary care visits highly personalized by giving doctors AI super powers that enable them to practice at the top of their license.

According to "The Washington Post", the Federal Trade Commission is investigating whether Teva and other companies are using slight changes to products to extend patents.

Verily Life Sciences has 25 employees in Tel Aviv and Haifa.

Fantasies of an AI revolution in drugs have met the reality of the industry's conservatism. But Teva’s head of R&D offers a glimpse into the AI tools his company actually uses, and is looking for. Startups take note.

Sensi.AI's advanced audio platform detects and predicts care events while ensuring privacy during home care.

The deal resolves all pending litigation on taxes payable by the company for 2008-2020.

Four new medical schools are planned in the coming years, but the government is not even aiming to reach the OECD average of doctors per thousand population.

The new financing comes several months after Insightec announced layoffs and a going concern qualification was attached to its financial results.

Revenue from trials by international companies in Israeli hospitals fell to NIS 518 million in 2023 from NIS 818 million in 2022.

After a 130% rise in its share price in the last year, the pharmaceuticals company has left the big two banks and Nice a long way behind.

The Israeli biotech company uses AI and computerized biology to develop smart antibodies.

Dr. Ronny Gal, Novartis's Chief Strategy and Growth Officer: Our aim is that half our innovative products should come from outside the company.

Dr. Avi Spier, Executive Director Business Development and Licensing at Novartis, on how to find successful partnerships.

Novartis’s Dr. Tamar Alon and Dr. Evan M. Beckman talk about the types of research that can drive the company's growth.

Eliran Elimelech, Startup Nation Central VP of Ecosystem Development: Most of the companies are in AI and pharma.

In Israel, Novartis focuses on marketing and clinical trials, but Country President Elad Maron says, "We know we can do much more. We want to make our mark beyond Israel in the biomedical industry."

Evercore ISI analyst Umer Raffat believes that sales could amount to more than $1 billion annually.

The Israeli pharmaceuticals company has reaffirmed its outlook for 2024 after higher revenue and a narrower loss in the first quarter of 2024.

Nectin develops novel targeted immunotherapies that address resistance to approved immune oncology treatments.

The Swiss-American ophthalmology company will pay $60 million immediately and up to $335 million with milestone payments for the company, BioLight reports.

Dot Compliance provides AI-based solutions for quality control in life sciences, where time is a great deal of money.

Beersheva's second hospital will be operated by Sheba Medical Center, and is due to open by 2028.